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Abstract
INTRODUCTION: Diabetes’ relationship to specific neuropathological causes of dementia is incompletely
understood.
METHODS: We used logistic regression to evaluate the association between diabetes and infarcts, Braak
stage, neuritic plaque score, and level of Alzheimer’s neuropathological changes in 2,365 autopsied
persons. In a subset of >1,300 persons with available cognitive data, we examined the association
between diabetes and cognition using Poisson regression.
RESULTS: Diabetes increased odds of brain infarcts (OR=1.57, P<0.0001), specifically lacunes (OR=1.71,
P<0.0001), but not Alzheimer neuropathology. Diabetes plus infarcts was associated with lower
cognitive scores at end of life than infarcts or diabetes alone, and diabetes plus high level of Alzheimer’s
neuropathological changes was associated with lower MMSE scores than the pathology alone.
DISCUSSION: This study supports the conclusions that diabetes increases the risk of cerebrovascular but
not Alzheimer’s pathology, and at least some of diabetes’ relationship to cognitive impairment may be
modified by neuropathology.

Keywords: diabetes, neuropathology, infarcts, autopsy, cognition, cerebrovascular, Alzheimer

Abbreviations: SMART: Statistical Modeling of Aging and Risk of Transition study; BRAiNS: Biologically
Resilient Adults in Neurological Studies; ROS: Religious Orders Study; HAAS: Honolulu-Asia Aging Study;
mABC: modified Alzheimer’s disease neuropathologic change rating based on Aβ plaque score, Braak
NFT (neurofibrillary tangle) stage, and CERAD NP (neuritic plaque) score.
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1. Introduction
A strong body of evidence links diabetes to cognitive dysfunction and dementia, including
clinically diagnosed Alzheimer’s disease (AD) and vascular dementia. Insulin resistance [1-3] and glucose
levels [4] have both been suggested as driving factors in the diabetes-dementia relationship. Many
researchers argue that diabetes and AD are closely linked, with shared biochemical etiologies [5], and
these hypotheses are supported by epidemiological studies that identified increased incidence of clinical
AD for people with diabetes [6-9]. Positron emission tomography (PET) imaging shows evidence of
glucose metabolic changes early in life among individuals at risk for developing AD [10]. Neuroimaging
studies have reported conflicting results regarding insulin resistance: Willette and colleagues (2015) [10]
reported increased amyloid deposition in normoglycemic, late middle-aged adults with higher levels of
insulin resistance [11], while Thambisetty and colleagues (2013) reported no association [12]; both
studies used 11C-Pittsburgh compound B PET, although insulin resistance was measured differently.
Insulin resistance has also been reported to be associated with higher cerebrospinal fluid tau levels in
APOE-ε4 allele carriers [13] and is increased in brain tissue in early AD [14].
Despite data linking diabetes and clinical AD, there are strong arguments that diabetes may not
exacerbate AD neuropathology. Clinicopathological studies have largely been unable to demonstrate
higher burden of AD neuropathology in persons with diabetes [15-18], except perhaps in APOE-ε4 allele
carriers [7, 9]. By contrast, studies often report increased cerebrovascular pathology [7, 9, 17].
Epidemiological, clinical, and neuroimaging studies have also identified increased risk of cerebrovascular
disease (CVD) linked to diabetes [19-21].
We re-examined the association between diabetes and neuropathology in a large
clinicopathological study (>2,000 total autopsies) drawn from the Statistical Modeling of Aging and Risk
of Transition (SMART) database, a consortium of longitudinal studies of aging and cognition [22]. We
assessed AD neuropathology and cerebral infarctions in aged participants with and without diabetes,
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controlling for age at death, sex, research center, and other potential confounders in a series of
regression models. We also evaluated the relative impact of diabetes on cognition using Mini-Mental
State Exam (MMSE) and Animal Naming Test (Animals) scores obtained near death.
2. Methods
2.1 Sample
Cases were drawn from participants in the SMART database [22]. Briefly, the database
comprises a standardized set of data elements contributed by 11 longitudinal studies of aging and
cognition. Most included cohorts have lengthy follow-up and high autopsy rates. Cohorts that required
or encouraged brain donation and collected information on diabetes are included in the current study.
Since not all deceased participants came to autopsy, and not all autopsies were included in the current
study, we assessed selection bias by comparing the included participants to all deceased participants in
the included cohorts with respect to age at death, gender, APOE-ε4, cohort, and diabetes. Inclusion
criteria for the current study were known diabetes status and non-missing data on at least one
neuropathological measure of both Alzheimer’s disease (either Braak neurofibrillary tangle [NFT] stage
[23] or Consortium to Establish a Registry in Alzheimer’s Disease [CERAD] neuritic plaque [NP] rating
[24]), and infarct neuropathology (large artery infarcts, lacunes, or microinfarcts). Based on availability
of necessary variables, participants from the following cohorts were included: Honolulu-Asia Aging Study
(HAAS) [25], Oregon Brain Aging Study [26], African American Dementia Project (see [22]), Klamath
Exceptional Aging Project [27], Religious Orders Study (ROS) [28], Rush Memory and Aging Project (Rush
MAP) [29], Memory and Aging Project at Washington University [30], and Biologically Resilient Adults in
Neurological Studies (BRAiNS) [31]. Research procedures were approved by Institutional Review Boards
at each cohort’s home institution. All participants provided written informed consent.
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2.2 Determination of diabetes
We determined diabetes status by self-report or by reported use of antidiabetic medication, as
previously described in ROS [32], Rush MAP [33], HAAS [7], and BRAiNS [34]. Although Type 1 and Type 2
diabetes were not differentiated, given the rarity of Type 1 diabetes in participants over age 60 and
especially over age 80 [35], we assumed that diabetes reports comprised Type 2 diabetes (hereafter
“diabetes”). Laboratory blood measures were not available in the SMART database, and therefore were
not examined in the present study.
2.3 Neuropathological outcomes
Autopsies were conducted within the original cohort studies [25, 26, 30, 31, 36, 37]. The
association between diabetes and neuropathology has been examined previously in some included
cohorts—HAAS [7], ROS [32], and BRAiNS [34]—but new endpoints are assessed and many additional
participants are included in the current study. Neuropathological assessments were performed blind to
clinical data. Neuropathological data were scored according to a format of the National Alzheimer’s
Coordinating Center (NACC) dataset, as described previously [22], because most SMART
neuropathologists contribute to NACC (see
https://www.alz.washington.edu/NONMEMBER/NP/rdd_np.pdf). Briefly, study neuropathologists made
determinations of Braak NFT stage [23]; CERAD NP rating (None, Sparse, Moderate, or Frequent) [24];
diffuse plaque rating (None, Sparse, Moderate, or Frequent); and presence of large artery cerebral
infarcts, lacunes, and cortical microinfarcts. “Large” infarcts were defined as any infarct with maximum
diameter greater than 1 cm; lacunes were defined as infarcts or hemorrhages 1 cm or less in diameter in
the small parenchymal vessels, but visible to the naked eye; and microinfarcts were defined as cortical
infarcts detected microscopically only.
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Since Thal phases (A immunohistochemistry) were unavailable, we constructed a modified
version of the National Institute on Aging-Alzheimer’s Association criteria for AD neuropathological
change (the “ABC” score) [38], that addressed the cases where diffuse amyloid plaque neuropathology
may be present without neuritic amyloid plaques. Thus, we collapsed the concept of diffuse amyloid
deposits to a dichotomous “Ad” variable. We considered the presence of any diffuse plaques to be Ad=1,
while absence of any diffuse plaques was 0. High level of AD changes corresponded to an Ad score of 1
plus Braak NFT stage V/VI plus CERAD NP rating of Frequent or Moderate. Intermediate level of AD
changes corresponded to an Ad score of 1 plus either Braak NFT stage V/VI plus None or Sparse CERAD
NP or Braak III/IV plus Frequent or Moderate CERAD NP. Low level of AD changes corresponded to an Ad
score of 1 plus either Braak NFT stage III/IV plus None or Sparse CERAD NP or Braak NFT stage 0/I/II. No
AD changes corresponded to an Ad score of 0 (absence of diffuse plaques) to enable compatibility with
the new consensus-based diagnostic criteria.
2.4 Covariates
Participant age at death (centered at 85 years), sex (female=1, male=0), education (years),
APOE-ε4 carrier status (any ε4 alleles=1, no ε4 alleles=0), hypertension (yes=1, no=0), and research
center were included as potential confounders.
2.5 Cognitive data
Global cognition was estimated using the MMSE [39] and category fluency using Animals [40] in
participants for whom those scores were available. Two sets of scores were examined: scores obtained
within two years of death, and scores obtained six years prior to death. MMSE and Animals were
selected because all cohorts administered Animals, and all cohorts except for one administered the
MMSE.
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2.6 Statistical Analysis
All statistical analyses were performed using SAS 9.4® (SAS Institute, Inc; Cary, NC). Two-group
comparisons of potential confounding variables for participants with and without diabetes were made
using t tests for interval-level variables and chi-square tests for categorical variables. We used casecontrol designs, where cases demonstrated the neuropathological outcome of interest and controls
were free of the neuropathology, to estimate adjusted odds ratios (OR) and 95% confidence intervals
(CI) for the association between neuropathological outcomes and diabetes. For multi-level variables
(mABC rating, Braak NFT stage, and CERAD NP score), we used the “absent” category (e.g., CERAD NP
score of ‘None’) as the reference level and computed an OR for each stratum separately; we conducted
sensitivity analyses using ordinal logistic regression models.
To address confounding, we used logistic regression to estimate adjusted ORs. For each
dependent neuropathological measure, we constructed two models. The first model included control
variables age at death, sex, and center. The second model included these variables plus education,
hypertension, and APOE-ε4 status. There was a loss in sample size in the second model due to missing
data in some of the additional variables. Significance for neuropathological models was set at 0.05, but
we also used the Holm-Bonferroni procedure to assess the robustness of the results given there were 26
comparisons made.
Last, we evaluated the association between diabetes and end-of-life global cognition and
category fluency. We estimated mean scores using Poisson regression and controlled for
neuropathology (mABC rating, and, in separate models, any infarcts or lacunes). Interactions between
diabetes and neuropathology were tested in the initial models. We adjusted mean scores for age at
death, education, sex, center, and time (in years) since last assessment. Given the lengthy follow-up of
most SMART cohorts, we also examined adjusted mean MMSE and Animals scores for participants with
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scores available six years prior to death. Assessments that occurred between 5.5 and 6.5 years prior to
death were included in this analysis. Significance for cognitive models was set at 0.05.
3. Results
There were 6,143 deaths in the included cohorts. Of the 2,429 total autopsies, 2,365 (97.4%)
were included in the current study. Participant inclusion is shown in Figure 1. Probability of inclusion in
the present study, conditioned on death, was independent of diabetes and depended only on cohort
(P<0.0001), since cohorts had different protocols for obtaining brain donation, and on age, such that a 1year increase in age at death increased the odds of inclusion by about 1% (P=0.048). Sex, APOE, and
diabetes status had no association with the probability of inclusion in the study after controlling for
cohort.
Participants with diabetes (n=507; 21.4% of total sample) died younger, had lower educational
attainment, and were more likely to have hypertension than participants without diabetes (n=1,858)
(Table 1). Last cognitive diagnosis was similar by diabetes status, and where dementia subtype was
classified, proportions of clinical AD (68% vs. 73%) and vascular dementia (29% vs 22%) were similar in
participants with and without diabetes, respectively (P=0.33). APOE-ε4 carrier status was similar among
those with and without diabetes. APOE was missing in 1.8% of cases with and in 2.2% of cases without
diabetes. Because participants without diabetes were almost twice as likely to be missing hypertension
(7.9% vs. 4.3%), we performed a sensitivity analysis that assumed all missing cases in the no diabetes
group had hypertension; the proportion with hypertension in the diabetes group remained significantly
higher than in those without diabetes (χ2=36.2, P<0.0001). Diabetes was reported during follow-up for
an average of 6.8±4.6 years.
Neuropathological outcome measures were incompletely observed in only a small proportion of
cases, with the exception of microinfarcts, which were missing in 23% of participants with diabetes
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(Table 2). Participants with diabetes had an estimated 54-57% increased odds of having any infarct
(P<0.0001 in Model 1; P=0.001 in Model 2) and had an estimated 71-77% increased odds of having
lacunes (P<0.0001 in both models) (Table 3). Prevalence of large infarcts and microinfarcts did not differ
by diabetes status, but participants with diabetes had marginally increased odds of having three infarct
types observed (P=0.05, Model 1; P=0.04, Model 2). There was no statistically significant association
with AD neuropathology, although there was some evidence that Low or Intermediate level of AD
neuropathology (vs. None) may be more common among participants with diabetes (Table 3). Results
were similar when we used ordinal rather than stratified logistic models (data not shown).
The association of diabetes with cognitive scores was modified by presence of any infarcts
(P=0.0016 for interaction; see Table 4 for means). Specifically, diabetes was associated with end-of-life
global cognition (MMSE) and category fluency (Animals) for participants with any infarcts. The presence
of diabetes in the absence of any infarcts was not associated with worse scores on either measure, but
participants who had both diabetes and any infarcts were significantly worse on both measures than
participants with infarcts alone (MMSE: ∆=-1.1 points, P=0.0002; Animals: ∆=-0.6 points, P<0.0001).
Results were similar for lacunes (Table 4). For participants with ‘High’ mABC rating, diabetes was
associated with lower MMSE scores than participants with ‘High’ mABC but without diabetes (14.3 vs.
16.1; P=0.0008); MMSE scores did not vary by other levels of mABC according to diabetes status. There
was no difference in Animals scores associated with diabetes and mABC (P=0.27). When neuropathology
was removed from the models, diabetes had no significant effect on either mean MMSE or Animals
scores. For assessments made six years prior to the end of life diabetes had no effect on mean MMSE or
Animals scores, either by modifying the effect of neuropathology, which was specified identically to the
previous models, or as a main effect (data not shown). As with end-of-life scores, diabetes had no
significant association with mean MMSE or Animals scores obtained six years prior to death when
neuropathology was removed from the models. In a sensitivity analysis examining slopes of change
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between two and six years before death, we found no mean differences associated with diabetes (data
not shown).
4. Discussion
Results from this autopsy study of about 2,400 older persons with and without diabetes, the
largest to date, confirm that diabetes is significantly associated with brain infarction, specifically lacunes.
We also found that diabetes in combination with infarcts was associated with lower MMSE and Animals
scores at the end of life compared to infarcts alone. By contrast, in this large sample, there was little
evidence that diabetes was associated with any AD neuropathology measure (global or more specific
measures). For participants with the highest level of AD changes, diabetes was associated with lower
mean MMSE but not Animals scores.
The link between diabetes and CVD has been demonstrated repeatedly in the scientific,
including epidemiologic, literature [19, 41-43]. The mechanisms through which diabetes causes CVD
remain incompletely understood, but may involve insulin resistance, high fasting blood glucose,
hypertension, comorbid abdominal obesity, carotid disease, endothelial dysfunction, and
hypercoagulation, among other mechanisms (see [44] for a review).
Neuropathological studies have repeatedly identified increased CVD, specifically brain
infarction, in association with diabetes, [9, 17, 32, 34]. However, the results are somewhat more
heterogeneous than this statement suggests. Sonnen and colleagues reported increased microvascular
infarcts in persons with diabetes, but only when dementia was also present [17]. Similarly, Nelson and
colleagues reported increased microinfarcts but without regard to cognitive status [34]. They also
reported an increase in the presence of any infarct (including large infarcts, lacunes, microinfarcts, and
hemorrhagic infarcts). By contrast, Arvanitakis and colleagues [32] and Ahtiluoto and colleagues [9]
identified macroscopic infarcts, visible to the naked eye, regardless of size, and found a positive
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association. In the current study, we found that diabetes was associated with any infarct (any large
infarct, lacune, and/or microinfarct) and also lacunes specifically. An association between diabetes and
lacunes has also been reported in neuroimaging studies [45]. Although we did not find a relationship
between microinfarcts and diabetes such as has been previously reported [17, 34], the substantial
proportion of missing data on microinfarcts in participants with diabetes compared to those without
(23% vs 12%, P<0.0001) may affect comparability.
As with CVD, epidemiologic studies have largely identified increased risk of AD for people with
diabetes [6-9], although some have not [42, 46]. In experimental studies, including in postmortem
human tissue, brain insulin resistance has been identified as a feature of early AD [14], and abnormal
serine phosphorylation of insulin receptor substrate 1 was shown to be elevated in AD brains [3, 47] and
to be associated with pathologic tau in neurons [47]. Animal studies have reported that anti-diabetes
agents may protect against Aβ-induced defective insulin signaling [3] and reverse increases in Aβ levels
induced through high-fat diet [48].
Two autopsy-based studies of diabetes or related measures reported increased AD
neuropathology. Peila et al. [7] examined 216 cases from HAAS (a subset of the 769 cases from HAAS
included in the present study) and reported increased NFT in the hippocampus and cortex and increased
NP in the hippocampus for participants with both diabetes and APOE-ε4 allele, compared to participants
without either factor. This group did not have increased AD neuropathology compared to participants
with APOE-ε4 alone. Participants with diabetes alone did not have increased AD neuropathology on any
measure compared to participants without either factor. Matsuzaki et al. [1] reported on 135 autopsies
from participants in a population-based study of residents in Hisayama, Japan. Blood-based measures of
diabetes obtained 10-15 years prior to death were used to predict Braak stage and CERAD NP score. No
associations with Braak stage were detected, but increases in 2-hour post-challenge glucose, fasting

12
insulin, and insulin resistance were associated with increased odds of any NP (but no graded effect for
increased NPs). APOE-ε4 plus hyperglycemia also increased odds of any NP.
Most studies with autopsy-verified measures have not supported a positive association between
diabetes and amyloid or tau neuropathology. The absence of an autopsy-verified diabetes-AD
relationship in these studies is conspicuous, considering that AD markers were measured and quantified
with a variety of techniques, including immunocytochemistry [15], immunohistochemistry [7, 9, 16, 32,
34], silver staining [9, 32, 34], and biochemical analysis [17]. Moreover, the lack of positive association
between diabetes and frequency or severity of AD neuropathology is independent of the
operationalization of neuropathology: Braak NFT staging [15, 17, 34], NFT density [9, 18, 32, 34], CERAD
NFT [16] and NP ratings [15, 16, 17, 34], NP density [9, 18, 34], β-amyloid protein burden [9, 32], and,
here, modified ABC rating.
In addition to the association of diabetes with brain infarction, we also found that diabetes, in
combination with any brain infarction, as well as lacunes specifically, was associated with significantly
lower MMSE and Animals scores at the end of life. It is unclear why diabetes was associated with
cognitive impairment only near death, and future research should address more directly the temporal
relationship between diabetes and cognitive outcomes. We did not find a strong relationship to
cognition for diabetes alone or in combination with mABC score, although participants with ‘High’ mABC
and diabetes had significantly lower MMSE scores, but not Animals scores, than participants with ‘High’
mABC but without diabetes. However, results pertaining to cognitive scores should be interpreted with
caution. Participants with diabetes were more likely to be missing MMSE scores (26.6% vs. 18.0%
missing, P<0.0001), and participants with missing Animals scores tended to be older. For both
instruments, participants with missing data were less educated, were more likely to have any infarcts
and were less likely to have high or intermediate mABC rating (data not shown).
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Our study has several strengths. This is the largest study to date of diabetes and neuropathology
of AD and CVD. We used data from detailed neuropathological assessments. This is the first study, to
our knowledge, to examine the association between diabetes and ABC rating. We also used other
established methods to diagnose or stage AD neuropathology. There was no evidence of selection bias
with regard to sex, education, APOE, or diabetes status within each cohort.
This study has some limitations. This is an observational study, and causal relationships cannot
be established. Although we controlled for confounding factors, we did not have available data on
adiposity or smoking habits; smoking is likely related to both risk of cerebrovascular pathology and other
lifestyle factors that may be related to diabetes. Diabetes was ascertained via self-report and medication
inspection rather than laboratory blood measures, so cases were likely missed. We used semiquantitative rather than quantitative measures of neuropathology, but as noted above findings in this
area have been rather consistent independent of the neuropathological methods used. We used a
modified ABC rating due to unavailability of Thal phases; this may have resulted in a very small
proportion of cases receiving a different ABC classification than they would have otherwise. This study
combined autopsied cases assessed by multiple neuropathologists, who may have had slightly different
criteria for classifying neuropathology. However, we also view this as a strength because a multi-center
approach, which synthesizes findings from multiple pathologists, approximates the experience of
community neuropathologists. Finally, our findings may not be generalizable to the general older adult
population given the differences in recruitment methods and source populations in each cohort.
Nonetheless, overall the findings are consistent with previous literature.
Based on our results, and the results of many prior clinicopathological studies, diabetes,
measured as a dichotomous variable, is unlikely to be significantly associated with AD neuropathology
but is likely to be significantly associated with CVD pathology. However, diabetes is heterogeneous.
Individuals differ in disease severity and duration, treatments used, comorbidities, and lifestyle factors.
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More research is needed to better account for these complicating factors, as well as survival bias or
perhaps compensatory mechanisms that may be at play, and identify subgroups that may be at
increased risk for AD.
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Tables
Table 1. Demographic and clinical characteristics of autopsied SMART subjects with known diabetes
status and available neuropathological data

Age at death, years

All subjects
(N=2,365)
88.7±6.5

Diabetes
(N=507)
87.8±6.0

No Diabetes
(N=1,858)
89.0±6.6

P value*
<0.0001

Female (n [%])

1009 (42.7)

147 (29.0)

862 (46.4)

<0.0001

14.1±4.2

13.7±4.2

14.3±4.2

0.002

1,600 (67.7)

413 (81.5)

1,187 (63.9)

<0.0001

543 (23.0)

103 (20.3)

440 (23.7)

0.12

Education, years
Hypertension (n [%])
APOE-ε4 carrier (n [%])
Last clinical diagnosis (n [%])

0.69

Intact cognition

948 (40.1)

204 (40.2)

744 (40.0)

Mild Cognitive Impairment

473 (20.0)

95 (18.7)

378 (20.3)

Dementia

908 (38.4)

198 (39.1)

710 (38.2)

36 (1.5)

10 (2.0)

26 (1.4)

MMSE, 6 years prior to death†

27.0±3.8

27.3±3.0

26.9±4.0

0.20

MMSE, ≤ 2 years of death‡

22.2±8.4

21.9±8.4

22.2±8.4

0.58

Animals, 6 years prior to death§

15.0±5.6

14.8±5.7

15.1±5.6

0.63

Animals, ≤ 2 years of death¶

10.7±6.1

10.1±5.9

10.9±6.1

0.032

Other/Unknown

*Comparisons are Diabetes vs. No Diabetes; diabetes is determined by self-report or report of antidiabetes
medication use. †Diabetes, n=179; No Diabetes, n=746. ‡Diabetes, n=244; No Diabetes, n=1092. §Diabetes,
n=200; No Diabetes, n=775. ¶Diabetes, n=339; No Diabetes, n=1167. Results presented are mean ± standard
deviation unless otherwise noted.
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Table 2. Cerebrovascular disease and Alzheimer’s disease neuropathologies (N=2,365).
Neuropathology (n [%])
Cerebrovascular disease pathology
Any infarcts
Missing any infarcts†
Large artery infarcts‡
Missing large artery infarcts
Lacunes§
Missing lacunes
Microinfarcts¶
Missing microinfarcts
Number of infarct types
0
1
2
3
Alzheimer’s disease neuropathology
Braak NFT stage
0/I/II
III/VI
V/VI
Missing
CERAD neuritic plaque rating
None
Sparse
Moderate
Frequent
Missing
Modified Alzheimer’s ABC rating#
No AD changes
Low AD changes
Intermediate AD changes
High AD changes
Missing

Diabetes
(N=507)

No Diabetes
(N=1,858)

354 (69.8)
24 (4.7)
129 (25.4)
2 (0.4)
283 (55.8)
4 (0.8)
140 (27.6)
118 (23.3)

1,105 (59.5)
62 (3.3)
389 (20.9)
16 (0.9)
749 (40.3)
24 (1.3)
519 (27.9)
226 (12.2)

P value*
<0.0001
0.034
<0.0001
0.11
<0.0001

153 (30.2)
202 (39.8)
106 (20.9)
46 (9.1)

753 (40.5)
661 (35.6)
336 (18.1)
108 (5.8)

160 (31.6)
213 (42.0)
102 (20.1)
32 (6.3)

512 (27.6)
793 (42.7)
418 (22.5)
135 (7.3)

ref
0.20
0.08

161 (31.8)
110 (21.7)
154 (30.4)
82 (16.2)
0

566 (30.5)
374 (20.1)
566 (30.5)
384 (20.7)
0

ref
0.86
0.42
0.022

138 (27.2)
149 (29.4)
119 (23.5)
86 (17.0)
15 (3.0)

472 (25.4)
481 (24.9)
462 (24.9)
357 (19.2)
86 (4.6)

ref
0.67
0.37
0.21

*P values are for results of chi-square tests. †Participant has no recorded infarcts but is missing data for at least
one infarct type. ‡One or more large artery cerebral infarcts. §One or more lacunes (small artery infarcts and/or
hemorrhages). ¶One or more cortical microinfarcts (including granular atrophy). #High AD changes = presence any
diffuse plaques plus Braak V/VI plus Frequent or Moderate neuritic plaques; Intermediate AD changes = presence
of any diffuse plaques plus EITHER Braak V/VI plus None or Sparse neuritic plaques OR Braak III/IV plus Frequent or
Moderate neuritic plaques; Low AD changes = presence of any diffuse plaques plus EITHER Braak III/IV plus None
or Sparse neuritic plaques OR Braak 0/I/II; No AD changes = absence of diffuse plaques.
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Table 3. Adjusted odds ratios for diabetes given presence of cerebrovascular disease and Alzheimer’s
disease neuropathology.
Neuropathology
(Dependent variable)
Cerebrovascular pathology
(present vs. absent)
Any infarcts

Model 1*
OR (95% CI)

Model 2†
OR (95% CI)

1.57 (1.23, 2.00) ‡§

1.54 (1.19, 2.00) ‡§

1.19 (0.94, 1.51)

1.17 (0.92, 1.49)

1.71 (1.39, 2.12) ‡§

1.77 (1.42, 2.20) ‡§

Microinfarcts

1.17 (0.90, 1.53)

1.16 (0.88, 1.54)

Three infarct types reported

1.44 (1.00, 2.09)

1.48 (1.01, 2.16)‡

V/VI vs. 0/I/II

0.82 (0.61, 1.11)

0.97 (0.70, 1.35)

III/IV vs. 0/I/II

0.92 (0.72, 1.18)

0.99 (0.76, 1.29)

Frequent vs. None

0.96 (0.68, 1.36)

1.25 (0.83, 1.87)

Moderate vs. None

1.02 (0.78, 1.33)

1.11 (0.83, 1.48)

Sparse vs. None

0.98 (0.73, 1.30)

1.07 (0.79, 1.46)

High vs. No AD changes

1.05 (0.76, 1.46)

1.13 (0.77, 1.65)

Intermediate vs. No AD changes

1.17 (0.86, 1.60)

1.34 (0.96, 1.87)

Low vs. No AD changes

1.22 (0.92, 1.60)

1.31 (0.98, 1.76)

Large artery infarcts
Lacunes

Alzheimer’s disease pathology
Braak NFT stage

CERAD neuritic plaque rating

Modified Alzheimer’s ABC rating

*Odds ratios are adjusted for age at death (centered at 85), female sex (1, 0), and research center (Honolulu-Asia
Aging Study, Oregon Health & Science University, Rush University Medical Center, Washington University, or
University of Kentucky). †In model 2, years of education, history of hypertension (1, 0), and APOE-ε4 carrier status
(1, 0) are included as additional control variables. ‡P value significant at 0.05. §P value statistically significant after
applying Holm-Bonferroni procedure.
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Table 4. Adjusted end-of-life mean Mini-Mental State Examination (MMSE) and Animal Naming
(Animals) scores*
MMSE
(n=1,317)
20.8 (0.4)†, ‡, §

Animals
(n=1,335)
9.4 (0.3)†, ‡, §

(2) No Diabetes + any infarcts

21.9 (0.3)¶

10.0 (0.2)¶

(3) Diabetes + no infarcts

24.9 (0.5)

11.5 (0.4)

(4) No Diabetes + no infarcts

23.7 (0.3)

11.3 (0.2)

(1) Diabetes + lacunes

MMSE
(n=1,302)
20.8 (0.5)†, ‡, §

Animals
(n=1,128)
10.1 (0.4)†, ‡, §

(2) No diabetes + lacunes

22.2 (0.3)**

11.0 (0.3)¶

(3) Diabetes + no lacunes

24.3 (0.5)

12.5 (0.4)

(4) No diabetes + no lacunes

23.2 (0.3)

12.2 (0.2)

Participant group
(1) Diabetes + any infarcts

Participant group

*Scores obtained within two years of death. Results are mean (SEM). Means are adjusted for modified
ABC rating, age at death, education, female sex, research center, and time between last assessment and
death. †(1) vs. (2) P<0.05 ‡(1) vs. (3) P <0.0001. §(1) vs. (4) P <0.0001. ¶(2) vs. (4) P <0.0001. #(1) vs. (2)
P < 0.05 **(2) vs. (4) P < 0.05.
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Figures
Figure 1. Participant inclusion flow diagram
6,143 deaths from included cohorts

2,429 autopsies (39.5% of deaths)

14 missing diabetes data
(0.6% of autopsies)
50 missing all pathological measures
(2.1% of autopsies)

2,365 autopsies includeda
(97.4% of autopsies)
a. Honolulu-Asia Aging Study (n=769), the Oregon Brain Aging Study I and II (n=77 and 32), the African
American Dementia Project (n=1), the Klamath Exceptional Aging Project (n=80), the Religious Orders
Study (n=555), the Memory and Aging Project at Rush University Medical Center (n=454), the Memory
and Aging Project at Washington University (n=126), and the Biologically Resilient Adults in Neurological
Studies (n=271).

